BACH2 is a major risk locus for Addison's disease, according to a study published in the Journal of Internal Medicine.
In the United Kingdom, rates of the disease were highest for those born in December, while in Poland, rates were highest for those born in January.
The first-ever guideline from Endocrine Society on Addison's disease details specifics of diagnostic tests and glucocorticoid therapy.
Adrenal insufficiency appears to impact patients differently and influences their beliefs about hydrocortisone replacement.
Addison disease patients may not benefit from continuous subcutaneous hydrocortisone infusion.
Endocrinology Advisor Articles
- Relationship Between HbA1c and Coronary Artery Disease
- DPP-4 Inhibitors and Incidence of Rheumatoid Arthritis in Type 2 Diabetes
- Cushing Syndrome Results in Poor Quality of Life Even After Remission
- Cost-Benefit Analysis of Insulin Analogs in Type 2 Diabetes
- Nonfunctioning Adrenal Incidentaloma Associated With Metabolic Syndrome
- Low Predictive Power of Biomarkers for Estimated Glomerular Filtration Rate Decline
- FDA to Review Gimoti for Diabetic Gastroparesis in Adult Women
- FDA Approves First Mobile App for Use in Preventing Pregnancy
- Hypothyroidism Predicts Atrial Tachyarrhythmia After AF Catheter Ablation
- Treating Painful Diabetic Peripheral Neuropathy With Electroacupuncture